肿瘤细胞治疗研究
英文原题：Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.
过去三十年间，淋巴增殖性疾病的治疗发生了深刻变化，尤其是由于越来越多有可能重新定义临床管理范式的创新疗法可供使用。
过去 30 年间，淋巴增殖性疾病的治疗发生了深刻变化，尤其是创新疗法日益增多，有望重新定义临床管理模式。单克隆抗体、免疫检查点抑制剂、双特异性抗体以及CAR-T（CAR-T）细胞疗法的开发产生了重要影响。本综述讨论针对各种血液系统恶性肿瘤的临床试验现状，重点介绍有前景的早期研究结果和克服耐药的策略。淋巴增殖性疾病涵盖多种病症：霍奇金淋巴瘤（HL）的目标是在一线治疗中整合免疫疗法，以减少化疗相关毒性；而外周 T 细胞淋巴瘤（PTCL）则缺乏有效靶向疗法。综述强调，治疗格局正转向精准医学，以及毒性更低而疗效更高的治疗方式。
Over the past three decades, the treatment of lymphoproliferative disorders has undergone profound changes, notably due to the increasing availability of innovative therapies with the potential to redefine clinical management paradigms. A major impact is related to the development of monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cell therapies. This review discusses the current landscape of clinical trials targeting various hematological malignancies, highlighting promising early-phase results and strategies to overcome resistance. Lymphoproliferative disorders encompass a range of conditions: while in Hodgkin lymphoma (HL) the goal is to reduce chemotherapy-related toxicity by integrating immunotherapy into the frontline setting, peripheral T cell lymphoma (PTCL) lacks effective targeted therapies. The review emphasizes a shifting therapeutic landscape towards precision medicine and treatment modalities that are less toxic yet more effective.
MEMBER ACCOUNT
登录成功会直接打开下一页。
